NLRP3 and Stroke: Ward et al. (2019) confirmed that MCC950 maintained the vascular integrity, attenuated brain edema, improved neurological outcome and cognitive function after stroke. Blockade of NLRP3 via MCC950 in both early-phase and post-reperfusion phase among transient ischemic models protects the mice from I/R injury by mitigating inflammation and stabilizing the BBB, particularly in a dose-dependent manner (Franke et al., 2021; Palomino-Antolin et al., 2021). Similar protective effects of MCC950 on BBB have also been documented by Ren et al. (2018) in ICH.